News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
131,322 Results
Type
Article (7727)
Company Profile (50)
Press Release (123543)
Multimedia
Podcasts (17)
Webinars (3)
Section
Business (41661)
Career Advice (255)
Deals (7054)
Drug Delivery (42)
Drug Development (18228)
Employer Resources (26)
FDA (3507)
Job Trends (3900)
News (64535)
Policy (4942)
Tag
2027 BioCapital Elite (1)
2027 BioCapital Standard (1)
2027 BioMidwest Elite (1)
2027 BioMidwest Standard (2)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (4)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (2)
2027 Genetown Standard (5)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (5)
40 Under 40 (1)
Academia (520)
Accelerated approval (15)
ADA (25)
Adcomms (4)
Allergies (53)
Alliances (6813)
ALS (40)
Alzheimer's disease (487)
Antibody-drug conjugate (ADC) (140)
Approvals (3810)
Artificial intelligence (178)
ASCO (92)
Autoimmune disease (104)
Automation (19)
Bankruptcy (40)
Belgium (6)
Best Places to Work (3083)
BIO (12)
Biologics (8)
BIOSECURE Act (5)
Biosimilars (53)
BioSpace Insights (31)
Biotechnology (29)
Bispecific (3)
Bladder cancer (83)
Brain cancer (19)
Breast cancer (288)
Cancer (1977)
Cardiovascular disease (190)
Career advice (237)
Career pathing (9)
CAR-T (76)
CDC (8)
CDMO (44)
Celiac Disease (1)
Cell therapy (229)
Cervical cancer (20)
Clinical research (17896)
Collaboration (480)
Commercialization (4)
Company closure (1)
Compensation (250)
Complete response letters (23)
COVID-19 (665)
CRISPR (34)
C-suite (199)
Cystic fibrosis (33)
Data (3143)
Denatured (4)
Depression (43)
Dermatology (72)
Diabetes (244)
Diagnostics (1400)
Digital health (18)
Diversity, equity & inclusion (9)
Drug discovery (84)
Drug pricing (43)
Drug shortages (8)
Duchenne muscular dystrophy (70)
Earnings (26270)
Editorial (13)
Employer branding (2)
Employer resources (23)
Events (18696)
Executive appointments (166)
Eye disease (2)
FDA (4814)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (10)
Frontotemporal dementia (14)
Funding (422)
Gene editing (72)
Generative AI (18)
Gene therapy (173)
GLP-1 (350)
Government (814)
Grass and pollen (3)
Guidances (275)
Healthcare (3993)
Hematology (53)
HIV (39)
Huntington's disease (31)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (60)
Immunology and inflammation (90)
Immuno-oncology (36)
Indications (90)
Infectious disease (759)
Inflammatory bowel disease (61)
Inflation Reduction Act (2)
Influenza (35)
Intellectual property (47)
Interviews (23)
IPO (3993)
IRA (8)
Job creations (951)
Job search strategy (208)
JPM (16)
Kidney cancer (5)
Kidney disease (37)
Labor market (38)
Layoffs (157)
Leadership (11)
Legal (857)
Licensing (12)
Liver cancer (23)
Longevity (10)
Lung cancer (342)
Lung diease (6)
Lymphoma (195)
Machine learning (15)
Management (6)
Manufacturing (345)
Marketing (2)
MASH (65)
Medical device (2711)
Medtech (2770)
Mergers & acquisitions (3476)
Metabolic disorders (551)
mRNA (61)
Multiple sclerosis (68)
Multispecific (1)
NASH (4)
Netherlands (4)
Neurodegenerative disease (124)
Neuropsychiatric disorders (26)
Neuroscience (926)
NextGen: Class of 2026 (1135)
Non-profit (959)
Now hiring (16)
Obesity (239)
Opinion (50)
Ovarian cancer (58)
Pain (74)
Pancreatic cancer (99)
Parkinson's disease (107)
Partnered (11)
Patents (99)
Patient recruitment (205)
Patient selection (12)
Peanut (13)
People (6022)
Peptides (6)
Pharmaceutical (16)
Pharmacy benefit managers (9)
Phase 1 (4489)
Phase 2 (7684)
Phase 3 (7113)
Pipeline (4237)
Policy (56)
Postmarket research (653)
Preclinical (1224)
Press Release (23)
Prostate cancer (86)
Psychedelics (22)
Radiopharmaceuticals (57)
Rare diseases (359)
Real estate (1082)
Recruiting (9)
Regenerative medicine (2)
Regulatory (4784)
Reports (19)
Research institute (484)
Resumes & cover letters (27)
Rett syndrome (14)
RNA editing (7)
RSV (17)
Schizophrenia (54)
Series A (72)
Series B (42)
Sickle cell disease (39)
Special edition (13)
Spinal muscular atrophy (56)
Sponsored (15)
Startups (557)
Stomach cancer (5)
Substance use disorders (3)
Supply chain (24)
Tariffs (22)
The Weekly (13)
Vaccines (310)
Venture capital (36)
Weight loss (170)
Wet AMD (1)
Women's health (38)
Worklife (5)
Date
Today (24)
Last 7 days (124)
Last 30 days (597)
Last 365 days (8054)
2026 (6144)
2025 (7966)
2024 (8278)
2023 (8417)
2022 (11044)
2021 (11313)
2020 (10353)
2019 (9154)
2018 (6975)
2017 (6070)
2016 (5656)
2015 (6509)
2014 (4306)
2013 (3095)
2012 (3618)
2011 (3858)
2010 (3250)
Location
Africa (158)
Alabama (24)
Arizona (78)
Arkansas (1)
Asia (8330)
Australia (1220)
California (3844)
Canada (936)
China (435)
Colorado (153)
Connecticut (172)
Delaware (156)
Europe (20792)
Florida (522)
Georgia (132)
Hawaii (2)
Idaho (11)
Illinois (320)
India (37)
Indiana (217)
Iowa (8)
Japan (225)
Kansas (34)
Kentucky (13)
Louisiana (25)
Maine (16)
Maryland (409)
Massachusetts (2859)
Michigan (73)
Minnesota (266)
Mississippi (4)
Missouri (37)
Montana (6)
Nebraska (6)
Nevada (76)
New Hampshire (28)
New Jersey (1507)
New Mexico (5)
New York (1025)
North Carolina (466)
North Dakota (1)
Northern California (2041)
Ohio (109)
Oklahoma (6)
Oregon (9)
Pennsylvania (743)
Puerto Rico (6)
Rhode Island (10)
South America (239)
South Carolina (10)
South Dakota (1)
Southern California (1555)
Tennessee (56)
Texas (559)
United States (13900)
Utah (115)
Virginia (59)
Washington D.C. (19)
Washington State (284)
Wisconsin (58)
131,322 Results for "40".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
BioSpace
40 Under 40 winners make their mark on biopharma
40 Under 40 honorees’ accomplishments include co-developing the world’s first synthetic biology programming language for mRNA and co-founding and leading a company acquired for $700 million up-front and up to $1.225 billion in total consideration.
October 6, 2026
·
3 min read
·
Angela Gabriel
Layoffs
Foghorn lays off 40% of staff after Lilly collaboration ends
Foghorn Therapeutics and Eli Lilly teamed up in 2021 to develop and commercialize oncology products. The biotech’s layoffs will leave the company with 65 employees as it refocuses on its proprietary portfolio programs.
October 1, 2026
·
2 min read
·
Angela Gabriel
Press Releases
BioStem Technologies Secures Up to $40 Million in a Committed Equity Facility
September 18, 2026
·
5 min read
Press Releases
Zealand Pharma – Completion of share buy-back program and related transactions (week 40 and 41, 2026)
October 5, 2026
·
3 min read
Job Trends
$40M in tax incentives expected to generate 1,600+ life sciences jobs in Massachusetts
Of the 38 companies receiving incentives, 31 will expand outside of Boston and Cambridge. Still, Boston and Cambridge are each expected to gain over 200 jobs. Tax incentive award recipients include AstraZeneca, Bristol Myers Squibb and Insulet.
September 30, 2026
·
1 min read
·
Angela Gabriel
Business
BioSpace
Honors 40 Under 40 Winners Whose Impact Reflects Industry’s Grit
The inaugural 40 Under 40 cohort includes CEOs, leaders who have founded or co-founded their company and executives from a range of disciplines. Winners’ accomplishments include shaping drug development, achieving key FDA milestones and launching a new field of study.
October 7, 2025
·
2 min read
·
Angela Gabriel
Cancer
Inhibrx’s OX40 agonist add-on beats Keytruda alone in head and neck cancer
Inhibrx CEO Mark Lappe was particularly keen on INBRX-106’s performance in patients with HPV-positive disease and sees a nearly $4 billion near-term opportunity thanks to the Phase 2 results.
September 8, 2026
·
5 min read
·
Annalee Armstrong
Press Releases
Calyxo Secures $40 Million Series F Financing as CVAC System Surpasses 40,000 Patients Treated for Kidney Stone Removal
April 15, 2026
·
3 min read
Press Releases
SCYNEXIS Announces $40.0 Million Private Placement
March 31, 2026
·
6 min read
Press Releases
Novo Nordisk STEP Young phase 3 data: 40.4% of children living with obesity achieved a BMI below the obesity threshold with semaglutide and lifestyle modification
September 7, 2026
·
7 min read
1 of 13,133
Next
